Synthetic Design Lab

Executive Summary

Synthetic Design Lab is a Boston-based preclinical biotechnology company founded in 2020, developing a proprietary next-generation antibody-drug conjugate (ADC) platform. Its technology aims to deliver payloads at least 10 times more effectively than current ADCs, potentially improving efficacy, safety, and versatility. The company is product-focused, with plans to advance its first therapy into clinical trials. By enhancing payload delivery, Synthetic Design Lab seeks to overcome key limitations of conventional ADCs, such as inadequate potency and off-target toxicity, expanding the therapeutic window for solid tumors and hematologic malignancies. The platform's differentiation lies in its ability to target traditionally undruggable antigens and increase the therapeutic index, positioning the company to capture significant value in the rapidly growing ADC market. In a competitive landscape dominated by major pharma and emerging biotechs, Synthetic Design Lab's strategy hinges on generating compelling preclinical proof-of-concept and securing partnerships or financing to advance toward the clinic.

Upcoming Catalysts (preview)

• Q3 2026Preclinical efficacy data in animal models70% success
• Q2 2027IND submission for lead ADC candidate40% success
• Q4 2026Series A or B financing round60% success